The Europe intra-articular injection for osteoarticular infiltrations market size is projected to reach US$ 157.08 million by 2031 from US$ 97.43 million in 2023. The market is expected to register a CAGR of 6.2% during 2023–2031. The increasing number of clinical trials is expected to enhance the development of innovative products, which are likely to trend in the market during the forecast period.
The rising incidence of osteoarthritis and other orthopedic disorders among the aging population and advancements made in injection techniques are factors contributing to market growth. In addition, the introduction of new formulations, increased awareness about joint health and the benefits of intra-articular injection, and higher healthcare spending in Europe that allows for better access to advanced treatment options, including intra-articular injections, are likely to fuel the Europe intra-articular injection for osteoarticular infiltrations market growth in the upcoming years.
Osteoarthritis is an inflammatory degenerative disease characterized by the deterioration of articular cartilage and underlying bone that predominantly affects the hip and knee. The increasing prevalence of osteoarthritis among the aging population, the growing need for effective treatments, and increased awareness among healthcare professionals and patients regarding the benefits of collagen injections have propelled the demand for intra-articular injections, thereby favoring the market growth. Recent advancements in hyaluronic acid injection therapy have significantly expanded growth trajectory, such as new formulations of hyaluronic acid—Durolane—sold by Nordic Medical Solutions ApS in Denmark, have improved patient outcomes and are widely adopted in clinics.
Globally, osteoarthritis (OA) affects more than 500 million people, accounting for 7% of the world's population, including more than 10 million from France. According to the Centers for Disease Control and Prevention (CDC) report, OA represents a major cause of long-term disability. It is prevalent among athletes and people who sustain joint injury or trauma. It is also widely reported among women, accounting for 60% of the cases reported worldwide. According to the World Health Organization (WHO) report, the geriatric population is highly prone to the risk of OA. Although OA can affect anyone, the condition is most commonly observed in adults over 40 years of age. The Versus Arthritis 2024 report estimated that there were over 10 million people with OA in the UK, i.e., 5.4 million people suffering from knee OA and 3.2 million with hip OA. Additionally, according to the Osteoarthritis and Cartilage Open Journal published in 2024, there were ~5 million adults with knee OA patients in Germany, with an increasing prevalence of 7%. Thus, with the rising prevalence of OA, new therapy options such as intra-articular injections are gaining attention in Europe.
Intra-articular injection holds tremendous potential for the treatment of joint inflammation caused by injury or osteoarthritis. A few of the recent strategic initiatives by market players are mentioned below.
Thus, continuous developments in intra-articular injection for osteoarticular infiltrations with increasing collaborations and partnerships are expected to present significant growth opportunities in the Europe intra-articular injection for osteoarticular infiltrations market in the coming years.
The key segments that contributed to the derivation of the Europe intra-articular injection for osteoarticular infiltrations market analysis are type and end user.
The scope of the Europe intra-articular injection for osteoarticular infiltrations market report is mainly divided into Germany, the UK, France, Italy, Spain, Denmark, and the Rest of Europe. Germany held a significant share of the market in 2023. The growth of the market is driven by the growing elderly population, rising research and development activities, and advancements in intra-articular injections. Aging population has been a major contributor to the elevated demand for intra-articular injections for treating osteoarticular disorders in the country. Osteoarthritis in the lower extremities (hips and knees) causes more mobility loss than in the upper extremities. These conditions can be managed and treated with the use of knee hyaluronic acid injection treatment; thus, it has great potential for growth and provides a rewarding opportunity to the players serving in this market. In addition, the presence of various players offering intra-articular injection treatment and conducting clinical trials favors the market growth in Germany.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 97.43 Million |
| Market Size by 2031 | US$ 157.08 Million |
| Global CAGR (2023 - 2031) | 6.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The Europe intra-articular injection for osteoarticular infiltrations market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Europe intra-articular injection for osteoarticular infiltrations market are listed below:
The “Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
The rising prevalence of osteoarthritis and advancements in injection techniques are the most influential factors responsible for the market growth.
The Europe intra-articular injection for osteoarticular infiltrations market is estimated to register a CAGR of 6.2% from 2023 to 2031.
The value of the Europe intra-articular injection for osteoarticular infiltrations market is estimated to reach US$ 157.08 million by 2031.
Bioventus Inc., SEIKAGAKU CORPORATION, Maxigen Biotech Inc., İstem Medical Inc., Sanofi SA, Ferring Pharmaceuticals, Fidia Pharma USA Inc., Biotech Healthcare Group, Bioteck S.p.A., and I+MED are among the key market players in the Europe intra-articular injection for osteoarticular infiltrations market.